Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences Inc.

The SPDR S&P 500 ETF Trust ($SPY) rallied 2.55% today, April 8, following news of a two-week ceasefire agreement between the United States and Iran...

Why Is the SPY ETF Up Today, 4/8/2026?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Corbus Pharmaceuticals (CRBP), Armata Pharmaceuticals (ARMP) and ...

Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP), Armata Pharmaceuticals (ARMP) and Moderna (MRNA)

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), rose 2.63% in today’s pre-market trading after President Donald Trump announ...

Why Is Vanguard S&P 500 ETF (VOO) Rallying Today, 4/8/2026?

The SPDR S&P 500 ETF Trust ($SPY) gained 0.04% today, April 7, as investors reacted to optimistic news regarding diplomatic efforts to calm Middle ...

Why Is the SPY ETF Up Today, 4/7/2026?

The SPDR S&P 500 ETF Trust ($SPY) gained 0.47% today, April 6, driven by optimism regarding a potential ceasefire deal between the U.S. and Iran an...

Why Is the SPY ETF Up Today, 4/6/2026?

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), rose a modest 0.06% in today’s pre-market trading, as investors awaited Tues...

Why Is Vanguard S&P 500 ETF (VOO) Up Today, 4/6/2026?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rocket Pharmaceuticals (RCKT) and Moderna (MRNA). Rocket Pharmace...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT) and Moderna (MRNA)

Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna (MRNA) is advancing a large Phase 3 study called “A Study of mRNA-1018...

Moderna Advances Phase 3 H5 Bird Flu Shot, Expanding Its Pandemic Vaccine Pipeline

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), closed 1.50% higher in Thursday’s trading following news that Iran and Oman ...

Vanguard S&P 500 ETF (VOO) Daily Update, 4/3/2026?

The SPDR S&P 500 ETF Trust ($SPY) gained 0.09% today, April 2, marking a continued rally driven primarily by hopes of de-escalation in the Iran con...

Why Is the SPY ETF Up Today, 4/2/2026?

The SPDR S&P 500 ETF Trust ($SPY) gained 0.75% today, April 1, due to rising optimism that the U.S.-Iran conflict could be approaching an end. Impo...

Why Is the SPY ETF Up Today, 4/1/2026?

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), rose 1.16% in Tuesday’s pre-market trading due to U.S. President Donald Trum...

Why Is Vanguard S&P 500 ETF (VOO) Up Today, 3/31/2026?

Cartesian Therapeutics ( ($RNAC) ) just unveiled an update. On March 26, 2026, Cartesian Therapeutics, Inc. disclosed that Board member Murat Kalay...

Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation

Alterity Therapeutics ( ($AU:ATH) ) has issued an announcement. Alterity Therapeutics has received positive written feedback from the U.S. Food and...

Alterity Wins FDA Backing on Key Elements of ATH434 Phase 3 Plan

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index ($SPX), fell 0.68% in pre-market hours on Friday. The drop comes as U.S. stock futu...

Why Is Vanguard S&P 500 ETF (VOO) Down Today, 3/27/2026?

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index ($SPX), fell 0.84% at Thursday’s market open. Overall, U.S. equities declined, weig...

Why Is Vanguard S&P 500 ETF (VOO) Down Today, 3/26/2026?

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), was down by 0.13% in Tuesday’s pre-market trading as oil prices rose amid re...

Why Is Vanguard S&P 500 ETF (VOO) Down Today, 3/24/2026?

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), was up by 1.57% in Monday’s pre-market trading as President Donald Trump sta...

Why Is Vanguard S&P 500 ETF (VOO) Up Today, 3/23/2026?

An announcement from Eterna Therapeutics ( ($ERNA) ) is now available. On March 18, 2026, Ernexa Therapeutics Inc. received notice from Nasdaq that...

Eterna Therapeutics Faces Nasdaq Delisting Risk After Notice

The SPDR S&P 500 ETF Trust ($SPY) tanked 1.43% today, March 20, as investors remain cautious about the ongoing Iran–U.S. conflict, which is raising...

Why Is the SPY ETF Down Today, 3/20/2026?

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), inched lower by 0.03% in Tuesday’s pre-market trading as oil prices spiked a...

Why Is Vanguard S&P 500 ETF (VOO) Up Today, 3/17/2026?

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), was up by 0.75% in Monday’s pre-market trading as Wall Street tried to recov...

Why Is Vanguard S&P 500 ETF (VOO) Up Today, 3/16/2026?

The SPDR S&P 500 ETF Trust ($SPY) was down 0.57% today, March 13, as investors were concerned about the escalating geopolitical conflict and its im...

Why Is the SPY ETF Down Today, 3/13/2026?

Cartesian Therapeutics, Inc. ($RNAC) announced an update on their ongoing clinical study. Cartesian Therapeutics (RNAC) is preparing a new phase 2 ...

RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch

Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna’s latest clinical update centers on its trial “Study to Evaluate the S...

Moderna’s Multi-Pathogen mRNA Study Reaches Completion, Supporting a Broader Vaccine Platform

The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alterity Therapeutics has introduced an opt-out unmarketable parcel sale f...

Alterity Therapeutics Launches Facility to Sell Small Share Parcels

The SPDR S&P 500 ETF Trust ($SPY) fell 0.13% today, March 11, due to a combination of geopolitical tensions in the Middle East, rising oil prices, ...

Why Is the SPY ETF Down Today, 3/11/2026?

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), was down by 0.14% in Wednesday’s pre-market trading due to ongoing tensions ...

Why Is Vanguard S&P 500 ETF (VOO) Down Today, 3/11/2026?

The SPDR S&P 500 ETF Trust ($SPY) fell 0.16% today, March 10, as investors reacted to rising Treasury yields, increased volatility, and concerns th...

Why Is the SPY ETF Down Today, 3/10/2026?

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is down 0.26% in pre-market hours on Tuesday. Overall, VTI ...

Vanguard Total Stock Market ETF (VTI) Daily Update—3/10/26

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mineralys Therapeutics, Inc. (MLYS – Research Repo...

Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC)

The SPDR S&P 500 ETF Trust ($SPY) rose 0.88% today, March 9, with support from a pullback in oil prices and easing geopolitical tensions. Important...

Why Is SPY ETF Up Today, 3/9/2026?

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biohaven Ltd. (BHVN – Research Report) and Cartesian...

Market Cap	$8.98B	P/E Ratio	NaN
52W High	$73.06	52W Low	$11.95
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-0.5%	52W Position	2.9%
Overall Score	33	Value Score	40
Quality Score	50	Technical Score	9

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RNA	$13.71	-2.00%	133.32K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RNA	$13.71	-2.0%	133.32K
3
4
5
6

RNA

RNA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Avidity Biosciences Inc. Data in Excel

Get Avidity Biosciences Inc. Data in Excel